CD19CAR/virus specific T cell therapy / Baylor College of Medicine - LARVOL DELTA

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Baylor College of Medicine | N=34 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov) - P1; N=34; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: Jan 2039 ➔ Aug 2040; Trial primary completion date: Jan 2024 ➔ Aug 2025

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov) - P1; N=34; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: Aug 2038 ➔ Jan 2039; Trial primary completion date: Aug 2023 ➔ Jan 2024

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov) - P1; N=34; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: Jan 2037 ➔ Aug 2038; Trial primary completion date: Jan 2022 ➔ Aug 2023

Clinical • Trial completion date • Trial primary completion date